DBV Technologies: Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

October 14, 2024 | Last Trade: US$7.98 0.07 0.88

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris ISIN Code: FR 0010417345

Date	Total number of shares	Total number of voting rights
09/30/2024	96,501,526	Total gross of voting rights: 96,501,526
09/30/2024	96,501,526	Total net* of voting rights: 96,199,467

* Net total = total number of voting rights attached to shares – shares without voting rights

Stock Quote

Last Trade:	US$7.98
Daily Change:	0.07 0.88
Daily Volume:	59,687
Market Cap:	US$163.750M

March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results... January 08, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study December 11, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old November 06, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results LOAD MORE NEWS

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE